Adjusted diluted EPS increased 28% to $1.19 per share, significantly outpacing adjusted EBITDA growth due to accretive share repurchases.
Adjusted gross profit grew 5% to $1.8 billion, supported by volume growth, improved cost of goods, disciplined inventory management, and increased private label penetration.
Net sales increased 3.8% to $10.1 billion, driven by 0.9% case volume growth and 2.9% food cost inflation and mix impact.
Operating cash flow increased by $104 million to $725 million year-to-date, supporting record capital investments and $273 million in share repurchases.
US Foods delivered record second quarter adjusted EBITDA of $548 million, a 12% increase year-over-year, with an all-time high adjusted EBITDA margin of 5.4%, up 40 basis points.
Footwear revenue declined 14% due to portfolio optimization and softer demand; apparel declined 1%, accessories grew 8%.
Gross margin improved by 70 basis points to 48.2%, driven by favorable currency, pricing benefits, and product mix, partially offset by channel mix and supply chain headwinds.
Inventory increased 2% to $1.1 billion; cash balance rose to $911 million following a $400 million senior notes issuance.
Operating income was $3 million, with adjusted operating income of $24 million after excluding restructuring and transformation charges.
Reported diluted loss per share was $0.01, adjusted diluted EPS was $0.02.
Under Armour reported Q1 2026 revenue of $1.1 billion, down 4% year-over-year, with regional declines in North America (-5%), APAC (-10%), and Latin America (-15%), while EMEA grew 10%.
Adjusted diluted EPS was $0.54 compared to $0.66 in Q2 last year.
Adjusted EBITDA was $45.9 million or 12.2% of sales, down from 13.3% last year, impacted by higher material and labor costs and footprint realignment expenses.
Automotive Climate and Comfort Solutions revenue increased 3.8% year-over-year (2.5% ex FX), partially offsetting planned revenue decreases from strategic exits.
Available liquidity increased to $416 million, up $15 million from prior year.
Gentherm delivered results in line with expectations in Q2 2025, improving adjusted EBITDA margin by over 100 basis points versus Q1.
Medical revenue decreased 3.8% year-over-year (4.8% excluding FX).
Operating cash flow year-to-date was $32 million; net debt stood at $81 million with net leverage ratio flat at 0.5 turns.
Adjusted EBITDA was $23.6 million, down $4.7 million from prior year, with a margin of 7.2%, up 30 basis points.
Adjusted EBITDA was $23.6 million, down $4.7 million from prior year, with a margin of 7.2%, up 30 basis points year-over-year due to disciplined cost management.
Cost savings exceeded original target, with $130 million in annualized reductions expected for 2025 compared to 2024.
Gross profit margin was 59.1%, flat versus prior year, supported by material cost reductions and manufacturing efficiencies.
Gross profit margin was 59.1%, flat versus prior year, supported by material cost reductions and manufacturing efficiencies offsetting volume deleverage.
Leverage ratio was 4.56x EBITDAR, within the 4.75x covenant maximum.
Leverage ratio was 4.56x EBITDAR, within the 4.75x covenant maximum, reflecting strong debt management.
Net sales for Q2 were $328 million, down 19.7% year-over-year, primarily due to a 30% cut in marketing spend.
Net sales for Q2 were $328 million, down 19.7% year-over-year, primarily due to a 30% cut in marketing spend and a shift towards lower-priced products.
Operating expenses were $185 million before restructuring, down 21% year-over-year and $51 million lower than Q1.
Operating expenses were $185 million, down 21% year-over-year and $51 million lower than Q1, driven by organizational redesign and cost-saving initiatives.
Dafinchi
